Webinar: ASSISTING BIOLOGISTS IN DISEASE RESEARCH BY MAKING EXPERT KNOWLEDGE ACCESSIBLE
Sponsored by: Thomson Reuters
Focused on:
Date: 8th February
Days old: 4746
Time: 3PM London/ 10AM New York
Impact of industry, non-profit organisation & academia collaborations on specific R&D therapy areas
Join us for a webinar hosted by Thomson Reuters and the Cystic Fibrosis Foundation on the impact of industry, academia, and non-profit organization collaborations on R&D in a specific therapy area.
An important aspect of systems biology research is utilization of knowledge management software to assist researchers in the discovery process.
This involves summarizing current literature, putting the content in context, and presenting it in a coherent and easily understood manner relevant to specific research interests to assist in data interpretation.
Thomson Reuters has created an original comprehensive technology for knowledge-based data analysis, broadly applicable through drug discovery and life science research.
This is why the CF Foundation approached GeneGo for creating a specialized discovery environment for cystic fibrosis, based on manual curation of current literature and functional data analysis tools.
The result was MetaMiner (Cystic Fibrosis), the pioneering MetaMiner project, developed in close collaboration with the CF Foundation over two years.
Elizabeth Joseloff, PhD, will briefly describe the CF Foundation's drug discovery model and focus on MetaMiner (CF) as a good example of a three-way collaboration between industry, academy, and a nonprofit organization.
Jerry Wright, PhD, project leader and coordinator from CF Foundation, will describe the scientific, managerial, and logistics issues behind the project.
Yuri Nikolsky, PhD, MBA, will describe the main components of the partnership that informs the program, the examples of pathology pathway maps, and case studies on the system's application in Cystic Fibrosis research and drug discovery.
For more information on the MetaMiner Partnerships program click here
Presented by
Elizabeth Joseloff, Ph.D,
Associate Director, Integrative Biology at Cystic Fibrosis Foundation Therapeutics, Inc
Elizabeth Joseloff is currently an Associate Director in the Medical Department at the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. Through working with pharmaceutical and biotechnology companies as well as academic research consortia, Elizabeth’s areas of focus at the CF Foundation include CF drug discovery and development, protein purification and protein structure-function relationships, systems biology, and biomarkers. Prior to joining the CF Foundation, Elizabeth spent 6 years at Celera as a Project Lead Scientist for proteomics identification of therapeutic monoclonal antibody targets and diagnostic biomarkers in oncology, primarily for lung cancer. Her industry experience includes tenure at Invitrogen (GIBCO Life Technologies). Elizabeth received a Ph.D. in Cancer Biology from the University of Arizona and completed post-doctoral training in skin cancer tumorigenesis at the National Cancer Institute in Bethesda, MD.
Jerry M. Wright, Ph.D,
Research Faculty, Physiology Dept., Johns Hopkins Medical Institutions
Jerry Wright is a research faculty member in the Department of Physiology in the School of Medicine at Johns Hopkins. In this position he provides expertise in planning initiatives in bioinformatics, systems biology, and information technology. He also is involved computer infrastructure and design for managing laboratory information flow. Currently, Jerry collaborates with multiple research laboratories to conduct data analysis and plan projects in Cystic Fibrosis research. He served as chairman of the scientific committee which incorporated expert Cystic Fibrosis knowledge into the GeneGo database and continues to update this information on a regular basis.
Yuri Nikolsky, Ph.D,
VP Research & Development at Thomson Reuters
Dr. Yuri Nikolsky has over ten years of experience in the life sciences industry, in business and research. Prior to joining GeneGo, a Thomson Reuters business, he was CEO of ChemDiv (San Diego, CA), a medicinal chemistry outsourcing company. Earlier, he co-founded and served as VP of Business Development at Integrated Genomics, Inc. (Chicago, IL), a comparative genomics and bioinformatics company. Dr. Nikolsky has also held positions as a Senior Scientist for Thermogen, Inc. (Chicago, IL) and as Research Associate (Instructor) at the University of Chicago. Dr. Nikolsky holds an MBA degree in Finance from the University of Chicago, a Master's degree in Biology from Moscow State University, and a Doctoral degree in Molecular Genetics from VNII Genetika Graduate School in Moscow, Russia.
Download Slides
Please login to download the slidesKey Learning Objectives
- How to mitigate risk of over spending time and resources in collaborative effort to manage a knowledge base development effort.
- Advancing in biology research by applying key external expertise.
- Impact of industry, non-profit organisation & academia collaborations on specific R&D therapy areas
- Relevance of Pathway Maps in therapy research and discovery projects
Audience
- CEO/President/Chairman/Executive Director
- CFO
- CIO/CTO/CISO/CSO
- COO
- Other C-Level Position
- Bioinformatics
- IT/IS - VP/Director/Manager
- Other IT
- Clinical Research
- Heads of Therapy Areas
- Heads of Discovery Technologies
- Head of Translational Research
- Target Identification Groups
- Lead Identification Groups
- Chemo informatics Groups
- Drug Repositioning Leaders
- Lead optimization Groups
- Compound Screening Groups
- Toxicologists
- Medical chemists
- Biologist